Rapid Development of Spatial Signatures as Predictive Biomarkers for Immunotherapy Response
The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to select responders that will be critical for the advancement of such treatments.
